View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter’s Weekly Newsletter
Andrew Huberman, Professor of Neurobiology at Stanford University and host of the Huberman Lab podcast joins us in a special journal club episode. Peter and Andrew each present a recent paper that sparked their interests, delving into the findings, dissecting their significance, discussing potential confounders and limitations, and exploring remaining questions. Importantly, they share their methodologies for comprehending research studies, providing valuable insights for listeners to navigate this process independently. Peter presents an epidemiological study reevaluating a noteworthy metformin result that intrigued the anti-aging community, leading to discussions on metformin's geroprotective potential (or lack thereof) and the current lack of aging biomarkers. Andrew introduces a paper examining how our beliefs about the medications we take influence their biological effects, distinguishing the "belief effect" from a placebo effect and highlighting its exciting implications for the future.
We discuss:
Connect With Peter on Twitter, Instagram, Facebook and YouTube
#195 - Freedom, PTSD, war, and life through an evolutionary lens | Sebastian Junger
#194 - How fructose drives metabolic disease | Rick Johnson, M.D.
#193 - AMA #31: Heart rate variability (HRV), alcohol, sleep, and more
#192 - COVID Part 2: Masks, long COVID, boosters, mandates, treatments, and more
#191 - Revolutionizing our understanding of mental illness with optogenetics | Karl Deisseroth M.D., Ph.D.
#190 - Paul Conti, M.D.: How to heal from trauma and break the cycle of shame
#189 - COVID-19: Current state of affairs, Omicron, and a search for the end game
Iñigo San Millán, Ph.D.: Zone 2 Training and Metabolic Health (Ep. #85 Rebroadcast)
#188 - AMA #30: How to Read and Understand Scientific Studies
#187 - Sam Apple: The Warburg Effect—Otto Warburg’s cancer metabolism theory
#186 - Patrick Radden Keefe: The opioid crisis—origin, guilty parties, and the difficult path forward
#185 - Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
Rick Johnson, M.D.: Metabolic Effects of Fructose (Ep. #87 Rebroadcast)
#184 - AMA #29: GLP-1 Agonists—The Future of Treating Obesity?
#183 - James Clear: Building & changing habits
#182 - David Nutt: Psychedelics & Recreational Drugs
#181 - Robert Gatenby, M.D.: Viewing cancer through an evolutionary lens and why this offers a radically different approach to treatment
#180 - AMA #28: All things testosterone and testosterone replacement therapy
#179 - Jeremy Loenneke, Ph.D.: The science of blood flow restriction—benefits, uses, and what it teaches us about the relationship between muscle size and strength
#178 - Lance Armstrong: The rise, fall, and growth of a cycling legend
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Huberman Lab
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.